440 related articles for article (PubMed ID: 31857776)
1. Tailored eradication
Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY
World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776
[TBL] [Abstract][Full Text] [Related]
2. Tailored eradication strategy
Choi YI; Chung JW; Kim KO; Kwon KA; Kim YJ; Kim JH; Seo JY; Park DK
World J Gastroenterol; 2021 Aug; 27(31):5247-5258. PubMed ID: 34497448
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients.
Cho JH; Jeon SR; Kim HG; Jin SY; Park S
J Gastroenterol Hepatol; 2019 Apr; 34(4):700-706. PubMed ID: 30011083
[TBL] [Abstract][Full Text] [Related]
4. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK
World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780
[TBL] [Abstract][Full Text] [Related]
5. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
6. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
10. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Kim SJ; Jee SR; Park MI; Jung K; Kim GH; Lee MW; Lee J; Jang JS; Koh M;
Medicine (Baltimore); 2022 Aug; 101(33):e30069. PubMed ID: 35984159
[TBL] [Abstract][Full Text] [Related]
12. Eradication Rate of
Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Lee HJ; Kim JI; Cheung DY; Kim TH; Jun EJ; Oh JH; Chung WC; Kim BW; Kim SS; Park SH; Kim JK
J Infect Dis; 2013 Oct; 208(7):1123-30. PubMed ID: 23801607
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
Chang YW; Shin GY; Kim JW; Moon JC; Chang EJ; Oh CH; Jang JY
Dig Dis Sci; 2022 Apr; 67(4):1222-1230. PubMed ID: 33755825
[TBL] [Abstract][Full Text] [Related]
16. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
[TBL] [Abstract][Full Text] [Related]
18. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
19. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
[TBL] [Abstract][Full Text] [Related]
20. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for
Cha B; Bang BW; Shin JB; Ko EJ; Ko W; Kwon KS; Shin YW; Suh YJ; Kim H
Scand J Gastroenterol; 2021 Sep; 56(9):1017-1022. PubMed ID: 34369255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
